OBJECTIVE: We sought to determine whether L -arginine polymer treatment of vein grafts enhances vascular production of nitric oxide and inhibits the development of neointimal hyperplasia. METHODS: External jugular veins of New Zealand White rabbits (n = 42) were harvested; treated intraluminally for 15 minutes with phosphate-buffered saline solution or L -arginine polymer 5, 7, or 9 at either 10 or 100 micromol/L; and then grafted into the contralateral carotid artery. Rabbits were killed after 28 days, and 5-microm sections of vessels were stained with hematoxylin and scored for intima/media ratio by using computerized morphometric analysis. Separate veins were treated in a similar fashion with biotinylated polymers and phosphate-buffered saline solution to assess for translocation efficiencies. Finally, vein segments pretreated with either phosphate-buffered saline solution or L -arginine polymers were cultured in Dulbecco's modified Eagle's medium containing lipopolysaccharide (100 microg/mL) and interferon gamma (200 U/mL) for 48 hours before measuring nitric oxide levels by means of the Griess reaction. RESULTS: Biotinylated L -arginine polymers demonstrated a dose- and length-dependent uptake into intimal and medial cells of treated vessels. Nitric oxide levels were significantly higher in vein segments treated with 100 micromol/L of L -arginine polymer 9 compared with control segments. Finally, the intima/media ratio also reflected both length- and concentration-dependent inhibition of neointimal hyperplasia.intima/media ratio PBS R5 R7 R9 10 micromol/L 0.909 +/- 0.072 0.920 +/- 0.073 0.861 +/- 0.138 0.710 +/- 0.122 100 micromol/L 0.924 +/- 0.061 0.581 +/- 0.089* 0.529 +/- 0.093* PBS, Phosphate-buffered saline solution; R, L -arginine polymer. *P <.001 versus phosphate-buffered saline solution and L -arginine polymer 5 controls (Bonferroni-corrected value). CONCLUSIONS: Arginine polymers of sufficient length and concentration were effective in increasing nitric oxide levels and reducing neointimal hyperplasia in this vein graft model.
OBJECTIVE: We sought to determine whether L -arginine polymer treatment of vein grafts enhances vascular production of nitric oxide and inhibits the development of neointimal hyperplasia. METHODS: External jugular veins of New Zealand White rabbits (n = 42) were harvested; treated intraluminally for 15 minutes with phosphate-buffered saline solution or L -arginine polymer 5, 7, or 9 at either 10 or 100 micromol/L; and then grafted into the contralateral carotid artery. Rabbits were killed after 28 days, and 5-microm sections of vessels were stained with hematoxylin and scored for intima/media ratio by using computerized morphometric analysis. Separate veins were treated in a similar fashion with biotinylated polymers and phosphate-buffered saline solution to assess for translocation efficiencies. Finally, vein segments pretreated with either phosphate-buffered saline solution or L -arginine polymers were cultured in Dulbecco's modified Eagle's medium containing lipopolysaccharide (100 microg/mL) and interferon gamma (200 U/mL) for 48 hours before measuring nitric oxide levels by means of the Griess reaction. RESULTS: Biotinylated L -arginine polymers demonstrated a dose- and length-dependent uptake into intimal and medial cells of treated vessels. Nitric oxide levels were significantly higher in vein segments treated with 100 micromol/L of L -arginine polymer 9 compared with control segments. Finally, the intima/media ratio also reflected both length- and concentration-dependent inhibition of neointimal hyperplasia.intima/media ratio PBS R5 R7 R9 10 micromol/L 0.909 +/- 0.072 0.920 +/- 0.073 0.861 +/- 0.138 0.710 +/- 0.122 100 micromol/L 0.924 +/- 0.061 0.581 +/- 0.089* 0.529 +/- 0.093* PBS, Phosphate-buffered saline solution; R, L -arginine polymer. *P <.001 versus phosphate-buffered saline solution and L -arginine polymer 5 controls (Bonferroni-corrected value). CONCLUSIONS:Argininepolymers of sufficient length and concentration were effective in increasing nitric oxide levels and reducing neointimal hyperplasia in this vein graft model.
Authors: Vinit N Varu; Sadie S Ahanchi; Melissa E Hogg; Hussein A Bhikhapurwala; Amy Chen; Daniel A Popowich; Ashley K Vavra; Janet Martinez; Qun Jiang; Joseph E Saavedra; Joseph A Hrabie; Larry K Keefer; Melina R Kibbe Journal: Am J Physiol Heart Circ Physiol Date: 2010-06-18 Impact factor: 4.733
Authors: Melissa E Hogg; Ashley K Vavra; Monisha N Banerjee; Janet Martinez; Qun Jiang; Larry K Keefer; Pierre Chambon; Melina R Kibbe Journal: J Surg Res Date: 2011-10-08 Impact factor: 2.192
Authors: Jingwei Sheng; George Oyler; Bin Zhou; Kim Janda; Charles B Shoemaker Journal: Biochem Biophys Res Commun Date: 2008-12-11 Impact factor: 3.575
Authors: Muneera R Kapadia; Lesley W Chow; Nick D Tsihlis; Sadaf S Ahanchi; Jason W Eng; Jozef Murar; Janet Martinez; Daniel A Popowich; Qun Jiang; Joseph A Hrabie; Joseph E Saavedra; Larry K Keefer; James F Hulvat; Samuel I Stupp; Melina R Kibbe Journal: J Vasc Surg Date: 2008-01 Impact factor: 4.268
Authors: Charles G Pearce; Samer F Najjar; Muneera R Kapadia; Jozef Murar; Jason Eng; Brian Lyle; Oliver O Aalami; Qun Jiang; Joseph A Hrabie; Joseph E Saavedra; Larry K Keefer; Melina R Kibbe Journal: Free Radic Biol Med Date: 2007-09-25 Impact factor: 7.376
Authors: Philipp Szalkiewicz; Maximilian Y Emmert; Paul P Heinisch; Zsuzsanna Arnold; Ingo Crailsheim; Markus Mach; Thomas Aschacher; Martin Grabenwöger; Bernhard Winkler Journal: Front Cardiovasc Med Date: 2022-07-28